#India #Bengaluru #Healthcare Access #Biosimilars #Biocon Biologics

Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biocon Biologics Ltd (BBL), an internationally recognized leader in biosimilars and a subsidiary of Biocon Ltd, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The event will be held in San Francisco, CA, and will feature a presentation by CEO Shreehas Tambe at 11:00 AM PST.

This conference is a significant opportunity for Biocon Biologics to emphasize its focus on providing equitable access to healthcare across the globe. The company's portfolio includes a wide array of biosimilars that cater to over 5 million patients in more than 120 emerging and advanced markets.

A Strong Focus on Healthcare

The main thrust of the presentation will be on the substantial impact that Biocon Biologics is making in expanding treatment options for patients, particularly in critical therapeutic areas such as oncology, immunology, and diabetes management. The firm has a robust pipeline with 10 approved products and several others in various stages of development.

In a statement, Shreehas Tambe remarked, "This year's J.P. Morgan Healthcare Conference marks an exciting milestone for Biocon Biologics as we celebrate the first anniversary of integrating the acquired global biosimilars business." He highlighted the company's commitment to showcasing the rapidly growing biosimilars portfolio, which is reflective of their innovative strategies and market expansion.

Innovations and Market Expansion

Looking forward, Biocon Biologics aims for a transformative year, packed with key product launches and strategic market expansions. The focus on research and development has allowed the company to lead in the biosimilars market which is crucial in meeting the unmet healthcare needs of millions.

Biocon Biologics has taken significant strides in ensuring that high-quality biological therapeutics are available at lower costs, thereby improving healthcare outcomes globally. Their products have been commercialized in key markets, including the U.S., Europe, Australia, Canada, and Japan. A total of 12 biosimilar assets are currently being developed, addressing a variety of non-communicable diseases.

Commitment to Sustainable Development

In alignment with their environmental, social, and governance (ESG) principles, Biocon Biologics is dedicated to advancing health standards globally while also tackling pressing health issues linked to sustainable development goals set by the United Nations. The company emphasizes creating a balance between business goals and contributions to societal wellbeing.

The presentation at the J.P. Morgan Healthcare Conference will also be shared via audio webcast following the event. Interested parties can access it along with additional information about Biocon Biologics through their investor relations website.

About Biocon Biologics Ltd

As a fully integrated biosimilars company, Biocon Biologics is committed to enhancing healthcare quality through innovative solutions. By leveraging their extensive research capabilities and manufacturing excellence, they strive to serve millions—ensuring access to effective and affordable treatments worldwide. With eight biosimilars already commercialized and a promising pipeline in the making, Biocon Biologics represents a beacon in the biopharma landscape.

For further updates, follow Biocon Biologics on social media platforms including X (formerly Twitter) and LinkedIn, or visit their official website at www.bioconbiologics.com.